If the United States is serious about maintaining its leadership in biopharmaceuticals, then it’s time for policymakers to articulate and embrace a robust sectoral competitiveness strategy.
March 30, 2020
Dozens of American drug companies and universities are rushing to create COVID-19 therapeutics—and they are better positioned to succeed than their counterparts anywhere else in the world.
February 6, 2020
Stephen Ezell presented about intellectual property’s impact on global health and life-sciences innovation at a Georgetown University course on Globalization and Public Health.
February 5, 2020
Severing the Link Between IP and Biomedical Innovation Isn’t the Answer to Global Health Care Challenges
Delinking the cost of R&D from the final prices of medicines and making governments the funders and planners of drug development would be rife with problems.
February 3, 2020
Separating the cost of biopharmaceutical research and development from the final market price of medicines would misalign incentives, raise bureaucratic costs, and limit innovation.
November 26, 2019
Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
November 25, 2019
Fact of the Week: A 40 Percent Reduction in U.S. Drug Prices Would Lead to as Much as 60 Percent Fewer Novel Compounds Reaching Clinical Testing
Proponents of capping drug prices often dismiss concerns about the impact on pharmaceutical R&D by pointing to the fact that drug prices are much lower internationally than in the United States. But this reasoning fails to consider that price restrictions in other countries have made pharmaceutical companies disproportionately reliant on revenue from the United States.
October 21, 2019
Fact of the Week: Artificial Price Controls Could Lower the Number of new Drugs by 3 to 5 Percent Over the Next Decade
In response to increased public pressure, both Congress and the Trump Administration have recently promoted efforts to reduce the price of prescription drugs in the United States. Several other countries have already imposed measures of their own.
September 18, 2019
Policymakers should recognize that the potential of data-driven drug development is crucial to the well-being of Americans as well as U.S. competitiveness, and develop policies to accelerate this transformation.
September 9, 2019
Academic studies consistently show that a reduction in current drug revenues leads to a fall in future research and the number of new drug discoveries.
August 12, 2019
China is challenging the United States for market share and jobs in one of the highest value-added, most innovation-intensive industries—and the risks extend not just to the U.S. economy, but to global biopharma innovation.